There are currently 47 ongoing clinical trials involving Polycythemia Vera
Of the 47 trials,29 trials are in Phase II
Furthermore, 6 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Polycythemia Vera, an Oncology condition. The largest number of ongoing clinical trials for Polycythemia Vera is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Polycythemia Vera-related drug trials.
University of Birmingham and University of Texas MD Anderson Cancer Center: The leading ongoing Polycythemia Vera related clinical trial sponsors
University of Birmingham and University of Texas MD Anderson Cancer Center are the top sponsors for Polycythemia Vera-related ongoing clinical trials.
Sidney Kimmel Cancer Center at Thomas Jefferson University, Zealand University Hospital, University of Chicago and AOP Orphan Pharmaceuticals GmbH are among other notable clinical trial sponsors involved in Polycythemia Vera. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Polycythemia Vera
Ruxolitinib (INCB18424, Jakafi, Jakavi), Melphalan (Alkeran, Melphalan Hydrochloride) and Cyclophosphamide (Cytoxan/Endoxana/Procytox/Genuxal/Sendoxan) are among the key marketed drugs involving Polycythemia Vera.
Ruxolitinib is an anti-neoplastic, immunomodulating and anti-inflammatory agent. It functions via Tyrosine Protein Kinase JAK1 Inhibitor; Tyrosine Protein Kinase JAK2 Inhibitor mechanism of action. Ruxolitinib is formulated as tablet for oral administration. Ruxolitinib was first approved in 2011 and is marketed globally in the US, UK, China, Japan, Germany, and France by several prominent pharma giants including Incyte Corp.
Melphalan (Alkeran, Melphalan Hydrochloride) is an alkylating agent of the bischloroethylamine type. It functions via DNA Synthesis Inhibitor. Melphalan is formulated as film coated tablets, coated tablets and tablets for oral route of administration and lyophilized injectable powder for solution for intravenous and Intraarterial route of administration. Melphalan was first approved in 1964 and is marketed globally in the US, UK, China, Japan, Germany, and France by several prominent pharma giants including Apotex Corp.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer